4:05 PM ET
10-Q
Financial Results
Artiva Biotherapeutics Q3 2026 Results: Net Loss of $28.8M, Loss Widens
Artiva Biotherapeutics is undergoing a significant strategic shift, including the wind-down of its AlloNK development program and a workforce reduction to preserve capital. The company is currently evaluating strategic alternatives to maximize stockholder value while managing its remaining clinical close-out and intellectual property activities.
- Key figure
- Net loss $28.8M